Kalbe Farma Owned By Conglomerate Boenjamin Setiawan Raises Revenue Of Rp12.37 Trillion And Profit Of Rp1.49 Trillion In Semester I 2021

JAKARTA - The pharmaceutical company, PT Kalbe Farma Tbk recorded performance growth in the first six months of this year. The revenue and profit of the issuer codenamed KLBF grew 'decently' throughout the first semester of 2021.

In KLBF's financial report published on the Indonesia Stock Exchange (IDX) website, quoted Monday, August 2, this company owned by conglomerate Boenjamin Setiawan scored revenue of Rp12.37 trillion in the first semester of 2021. This achievement increased by 6.6 percent from Rp11.6 trillion in the same period before.

Kalbe Farma's cost of goods sold also increased to Rp6.97 trillion from Rp6.35 trillion in the same period last year. As a result, gross profit was recorded at Rp5.39 trillion, up slightly from Rp5.25 trillion in the first half of last year.

Thus, the profit for the period attributable to owners of the KLBF parent entity became Rp1.49 trillion, up 7.93 percent from Rp1.38 trillion in the same period last year. The company's total assets also increased to Rp23.4 trillion from the position of Rp22.56 trillion at the end of 2020.

The increase occurred in non-current assets to Rp9.78 trillion from Rp9.48 trillion, while non-current assets increased to Rp13.62 trillion from Rp13.07 trillion. The company's total liabilities were recorded at Rp4.09 trillion, down from Rp4.28 trillion on December 31, 2020.

The decrease was mainly in long-term liabilities to Rp966.04 billion from Rp1.11 trillion, while short-term liabilities decreased to Rp3.12 trillion from Rp3.17 trillion.

Kalbe Farma's total equity was recorded at Rp19.31 trillion, up from Rp18.27 trillion at the end of last year. Meanwhile, the position of cash and cash equivalents as of June 30, 2021, was recorded at Rp4.6 trillion, up from Rp4 trillion as of June 30, 2020.